<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200456</url>
  </required_header>
  <id_info>
    <org_study_id>TP0003</org_study_id>
    <secondary_id>2019-000884-26</secondary_id>
    <nct_id>NCT04200456</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)</brief_title>
  <acronym>myOpportunITy1</acronym>
  <official_title>A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in
      maintenance treatment and asses safety and tolerability of rozanolixizumab in adult study
      participants with primary immune thrombocytopenia (ITP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigators are blinded to the treatment code, they will see the platelet values.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Durable Clinically Meaningful Platelet Response of ≥50x10^9/L during the last 12 weeks</measure>
    <time_frame>During the last 12 weeks (Week 13 to Week 25)</time_frame>
    <description>Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, as defined by proportion of study participants who have platelet responses for at least 8 out of 12 weeks during the last 12 weeks (Week 13 to 25)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of visits with Clinically Meaningful Platelet Response of ≥50x10^9/L</measure>
    <time_frame>From Baseline during Treatment Period (up to Week 25)</time_frame>
    <description>Number of weeks (visits) with platelet counts ≥50x10^9/L over the Treatment Period of the study (Week 1 to Week 25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined as platelet count ≥30x10^9/L and at least a 2-fold increase of the Baseline count confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding by visit</measure>
    <time_frame>From Baseline during Treatment Period (up to Week 25)</time_frame>
    <description>Response, defined as platelet count ≥30x10^9/L and at least a 2-fold increase of the Baseline count confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response defined as platelet count ≥100x10^9/L confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding by visit</measure>
    <time_frame>From Baseline during Treatment Period (up to Week 25)</time_frame>
    <description>Complete Response defined as platelet count ≥100x10^9/L confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinically Meaningful Platelet Response of ≥50x10^9/L: time from starting treatment to achievement of first response of ≥50x10^9/L</measure>
    <time_frame>Time from starting treatment to achievement of first response of ≥50x10^9/L (up to Week 25)</time_frame>
    <description>Time to Clinically Meaningful Platelet Response of ≥50x10^9/L: time from starting treatment to achievement of first response of ≥50x10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Meaningful Platelet Response of ≥50x10^9/L by Day 8</measure>
    <time_frame>Baseline to Day 8</time_frame>
    <description>Clinically meaningful Response defined as: platelet count ≥50x10^9/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue therapy</measure>
    <time_frame>From Baseline to first rescue therapy (up to Week 25)</time_frame>
    <description>Time to first rescue therapy use will be analyzed using a Cox Proportional Hazards model with fixed terms for treatment, splenectomy,degree of thrombocytopenia (platelet count &lt; or ≥ 15x10^9/L), and geographical region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined as change from Baseline at or above the defined threshold for ITP Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score</measure>
    <time_frame>From Baseline during Treatment Period (up to Week 25)</time_frame>
    <description>The ITP Patient Assessment Questionnaire (ITP-PAQ) responder rates will always be calculated relative to the Baseline and will be limited to the participants with a Baseline ITP-PAQ score at or above the applicable threshold score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From Baseline to end of Safety Follow-Up Period (up to Week 31)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of TEAEs leading to withdrawal of investigational medicinal product (IMP)</measure>
    <time_frame>From Baseline to end of Safety Follow-Up Period (up to Week 31)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Rozanolixizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rozanolixizumab</intervention_name>
    <description>Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.</description>
    <arm_group_label>Rozanolixizumab</arm_group_label>
    <other_name>UCB7665</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants receive placebo by subcutaneous infusion at pre-specified time points.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study participant must be ≥18 years of age at the time of the Screening Visit

          -  Study participant has a diagnosis of persistent (&gt;3 months duration) or chronic (&gt;12
             months duration) primary immune thrombocytopenia (ITP) at the Screening Visit

          -  Study participant has documented intolerance or insufficient response to one or more
             appropriate courses of standard of care ITP medication prior to Screening

          -  Study participants must have prior history of a response to a previous ITP therapy.

          -  If taking allowed immunosuppressive drugs, study participant must be on stable doses
             during defined time periods prior to Baseline (Day 1)

          -  Study participant has a documented history of low platelet count (&lt;30x10^9/L) prior to
             Screening

          -  Study participant has a platelet count measurement at Screening and at Baseline (Day
             1) with an average of the two &lt;30x10^9/L and no single count may be &gt;35x10^9/L (using
             local laboratories)

          -  Study participant has a current or history of a peripheral blood smear consistent with
             ITP

          -  Study participants may be male or female:

               1. A male participant must agree to use contraception during the Treatment Period
                  and for at least 3 months after the final dose of study treatment and refrain
                  from donating sperm during this period

               2. A female participant is eligible to participate if she is not pregnant as
                  confirmed by a negative serum pregnancy test or not planning to get pregnant
                  during the participation in the study, not breastfeeding, and at least one of the
                  following conditions applies:

        Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the
        contraceptive guidance during the Treatment Period and for at least 3 months after the dose
        of study treatment

        Exclusion Criteria:

          -  Participant has a history of arterial or venous thromboembolism (eg, stroke, transient
             ischemic attach, myocardial infarction, deep vein thrombosis or pulmonary embolism)
             within the 6 months prior to randomization or requires anticoagulant treatment

          -  Study participant has clinically significant bleeding that warrants immediate platelet
             adjustment (eg, menorrhagia with significant drop in hemoglobin)

          -  Study participant has a known hypersensitivity to any components of the
             investigational medicinal product (IMP) or comparative drugs (and/or an
             investigational device) as stated in this protocol

          -  Study participant has evidence of a secondary cause of immune thrombocytopenia from
             the past medical history (eg, bacterial or viral infection, past medical history of
             leukemia, lymphoma, common variable immunodeficiency, systemic lupus erythematosus,
             autoimmune thyroid disease) or to drug treatments (eg, heparin, quinine,
             antimicrobials, anticonvulsants) or participant has a multiple immune cytopenia, eg,
             Evan's syndrome

          -  Study participant has a clinically relevant active infection (eg, sepsis, pneumonia,
             or abscess) in the opinion of the investigator, or had a serious infection (resulting
             in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior
             to the dose of IMP

          -  Study participant with a known tuberculosis (TB) infection, at high risk of acquiring
             TB infection, or latent tuberculosis infection (LTBI), or current/history of
             nontuberculous mycobacterial infection (NTMBI)

          -  Study participant has a history of a major organ transplant or hematopoietic stem
             cell/marrow transplant

          -  Study participant has experienced intracranial bleed in the last 6 months prior to the
             Screening Visit

          -  Study participant has a history of coagulopathy disorders other than ITP

          -  Study participant has a Karnofsky Performance Status rating &lt;60% at the Screening
             Visit

          -  Study participant with current or medical history of immunoglobulin A (IgA)
             deficiency, or a measurement of IgA &lt;50 mg/dL at the Screening Visit

          -  Study participant has undergone a splenectomy in the 2 years prior to the Baseline
             Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1-844-599-2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1844599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tp0003 40190</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tp0003 20050</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tp0003 20158</name>
      <address>
        <city>Shinagawa-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tp0003 20051</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tp0003 40222</name>
      <address>
        <city>Skorzewo</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Japan</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP</keyword>
  <keyword>UCB7665</keyword>
  <keyword>Rozanolixizumab</keyword>
  <keyword>Primary immune thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rozanolixizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

